Products
Health is our passion and priority
Please see below a list of Astellas’ medicines with links to the Summary of Product Characteristics and Patient Leaflets for each provided:
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Haematology
XospataTM▼ (gilteritinib fumarate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Oncology
PadcevTM▼ (enfortubmab vedotin) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
XtandiTM (enzalutamide) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
VyloyTM (zolbetuximab) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Renal
EvrenzoTM▼ (roxadustat) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Transplantation
Advagraf TM(tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
ModigrafTM (tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
PrografTM (tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Urology
Flowmaxtra XLTM (tamsulosin hydrochloride) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Mirabegron-Astellas (mirabegron) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
VesomniTM (tamsulosin hydrochloride, solifenacin succinate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
VesicareTM (solifenacin succinate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)
Women’s Health
VeozaTM▼ (fezolinetant) | Summary of Product Characteristics▼ (SmPC) | Patient Leaflet (PIL)